The only company of its kind and scope in the world combining advanced DNA testing, the power of big data and decades of infectious disease expertise, Aperiomics is revolutionizing the way that medical professionals around the world identify infections. Supported by the National Science Foundation, Aperiomics pinpoints every known bacteria, virus, fungus, and parasite within the body through next-generation DNA testing, using its world-renowned database of 37,000 microorganisms to conduct advanced diagnostic research and solve medical mysteries.
Our visibility and valuation-raising campaign is educating the public and key stakeholders – including investors, insurance industry decisionmakers, healthcare providers, policymakers and regulators – about the promise of this new technology. Leveraging the company’s momentum as 2018’s “International Start Up of the Year,” Waxman Strategies has enhanced the company’s brand awareness through top-tier media attention and executive communications strategy.
- Generated coverage to bolster awareness of the company, its leadership, and its novel use of advanced computing and DNA sequencing through placements in The Washington Post, Washington Business Journal, NBC Today Show, and more.
- Elevated the founder’s profile to attract new investors prior to raising a Series A, secure new partners, navigate regulatory hurdles, and accelerate adoption by Medicare and Tricare.
- Enhanced the executive thought leadership presence by securing industry conference engagement and speaking opportunities at CNBC Healthy Returns, WSJ Global Health Forum, BIO, and HLTH.